Personalized Medical Care & Dedicated International Patient Concierge

4.9 Patient Satisfaction

en-US

Medical Clinic LogoMedical ClinicHome
Book Consultation
Book Consultation
Patient Guide
SpecialtiesServicesDoctorsOffersArticlesBefore & AfterReviewsAbout UsContact Us
Conjuran (Polynucleotide) Joint Injection Explained

Medical Guide

Conjuran (Polynucleotide) Joint Injection Explained

Conjuran is a polynucleotide (PN) joint injection framed as regeneration-oriented. See how it compares with hyaluronic acid and its US regulatory status.

Schedule a Consultation

Conjuran (Polynucleotide) Joint Injection Explained

Medically reviewed by Dr. Heejun Kim, Board-Certified Orthopedic Surgeon, Chief Director, Nucellin Orthopedic Clinic

Patients exploring non-surgical options for joint pain often encounter a growing menu of injectable treatments, and the terminology can be confusing. Hyaluronic acid, platelet-rich plasma, polydeoxyribonucleotide, and polynucleotide products are all discussed in similar contexts, yet they are different materials with different purposes and very different regulatory histories. This article focuses on one of them: Conjuran, a polynucleotide (PN) joint injection.

The goal here is a clear, honest explanation. We will cover what Conjuran is, how a polynucleotide joint injection is thought to differ from a lubrication-focused product, how it compares with hyaluronic acid viscosupplementation, and what the evidence currently supports. We will also be direct about the regulatory reality: Conjuran is not FDA-approved in the United States, the evidence base is still limited, and results vary. At Nucellin Orthopedic Clinic in Yongsan-gu, Seoul, treatments of this kind are provided under Korean medical regulation, and whether any injection is appropriate is decided by a physician after an in-person examination.

What Is Conjuran?

Conjuran is a brand of polynucleotide (PN) injection used in and around joints. Polynucleotides are chains of nucleotides, the building blocks of DNA, and in these products they are typically highly purified and derived from natural sources such as fish. Conceptually, polynucleotides are related to polydeoxyribonucleotide (PDRN), another regenerative-oriented material, but the products are formulated and marketed differently, and they should not be assumed to be identical.

What distinguishes the marketing of a polynucleotide joint injection is the emphasis. Conjuran is described as regeneration-oriented rather than lubrication-only. In other words, the stated intent is not simply to add a slippery, cushioning fluid to the joint, but to support the local tissue environment. That framing is central to understanding how Conjuran is positioned relative to more established injectables, and it is also where careful, honest language matters most, because "regeneration-oriented" describes an aim, not a guaranteed outcome.

Joint Lubrication vs Regeneration: Two Different Goals

To understand where Conjuran fits, it helps to separate two distinct ideas: joint lubrication vs regeneration.

Lubrication-focused injections aim to improve the mechanical environment of the joint. The classic example is hyaluronic acid, which is a naturally occurring component of joint fluid. When injected, hyaluronic acid is intended to supplement the joint's own fluid, improving cushioning and reducing friction, at least temporarily. The concept is often called viscosupplementation, and the primary target is symptom relief through better mechanics rather than tissue repair.

Regeneration-oriented injections, at least in intent, aim to influence the biology of the tissue itself, supporting the local repair environment rather than acting mainly as a mechanical cushion. Polynucleotide products such as Conjuran are marketed within this second category. It is important to read this framing carefully. Saying a product is designed to be regeneration-oriented is a description of its intended mechanism and marketing category; it is not a claim that it repairs cartilage, reverses arthritis, or produces permanent results. The honest position is that PN injection tissue regeneration is a concept supported by early and limited evidence, and outcomes vary from person to person.

How a Polynucleotide Injection Is Thought to Work

The proposed mechanisms for polynucleotide therapy joint pain draw largely on laboratory and preclinical research and should be understood as proposed rather than definitively proven for every clinical scenario. Polynucleotides are thought to act in two general ways.

First, as chains of nucleotides, they may supply raw material that cells can use, potentially supporting tissue that is metabolically stressed. Second, polynucleotides have physical properties that allow them to hold water and form a gel-like environment, which may contribute a degree of hydration and viscoelastic support within the joint. This dual character, a biological signal combined with a hydrating, gel-like presence, is why polynucleotides are sometimes described as sitting between purely mechanical lubricants and purely biological therapies.

Whether these proposed mechanisms translate into meaningful, lasting clinical benefit for a specific patient is a separate question, and the honest answer is that the clinical evidence is still limited. Some patients may experience symptom improvement; others may not. No responsible description of Conjuran should promise a cure, permanent relief, or a pain-free joint, and it should never claim to regrow cartilage or reverse arthritis.

Conjuran vs Hyaluronic Acid

A Conjuran vs hyaluronic acid comparison is one of the most useful ways to understand this treatment, because the two are often mentioned together but differ in an important regulatory respect.

Hyaluronic acid viscosupplementation is an established, FDA-approved option in the United States, but its approval is specific and limited. In the U.S., hyaluronic acid injections are approved as a medical device for knee osteoarthritis, not as a blanket approval for every joint or every condition. Their primary intended benefit is mechanical: supplementing joint fluid to improve cushioning and reduce friction, with the goal of easing symptoms. The evidence for hyaluronic acid in knee osteoarthritis has been studied for years and remains a subject of ongoing discussion among specialists, but the key point for this comparison is its regulatory status, an FDA-approved device for a specific knee indication.

Conjuran, by contrast, is not FDA-approved in the United States. It is a polynucleotide product marketed as regeneration-oriented rather than lubrication-only, and it belongs to a newer, less standardized category with a more limited evidence base. So the honest contrast is twofold. On mechanism, hyaluronic acid is framed primarily around lubrication and cushioning, whereas Conjuran is framed around supporting the tissue environment. On regulation, hyaluronic acid is an FDA-approved device for knee osteoarthritis in the U.S., while Conjuran is not FDA-approved at all. Neither of these facts makes one product universally superior; they simply describe different tools with different intended roles and very different regulatory standing. Which, if either, is appropriate for a given person depends on diagnosis and examination.

Regulatory Status: Not FDA-Approved in the US

For any reader in the United States, this section is essential. Conjuran, as a polynucleotide joint injection, is not FDA-approved in the United States. That is a plain statement of regulatory fact, and it stands in deliberate contrast to hyaluronic acid viscosupplementation, which is an FDA-approved device but only for knee osteoarthritis.

When a Conjuran injection Korea program is offered at a clinic such as Nucellin Orthopedic Clinic, the care is delivered under Korean medical regulation, not under U.S. FDA rules. Regulatory approval is country-specific: a product may be lawfully used in one country while having no U.S. approval. For patients traveling from the United States, that has practical consequences. The oversight framework is Korean, the applicable product standards are Korean, and this type of elective regenerative treatment is typically not covered by U.S. insurance. Disclosing this clearly is part of responsible communication, and it allows you to weigh the option with full information. You can learn more about the clinic's regenerative program on the Nucellin Orthopedic Clinic website.

What the Evidence Shows

Interest in a regenerative joint injection Seoul patients and international visitors may encounter has grown alongside a modest research literature on polynucleotides. Some early studies have explored polynucleotide injections for joint symptoms, and a portion of this work reports improvements in pain or function. This is a reasonable basis for cautious interest, and it is why clinicians who practice regenerative orthopedics discuss the option.

The evidence must be described accurately, however. Studies on polynucleotide joint injections tend to be relatively small, vary in design and protocol, and often follow patients for limited periods. Large, high-quality, long-term randomized trials that would allow strong, definitive conclusions remain limited, and polynucleotide products are not standardized across the board. The fair summary is that early evidence is promising for some outcomes in some patients, that the overall evidence base is limited, and that results vary. That is precisely why no guarantee should ever be attached to this treatment, and why claims of cure or cartilage regrowth are not supportable.

What to Expect During Evaluation and Treatment

A sound approach to any joint injection begins with diagnosis, not with the injection. That generally involves a detailed history, a physical examination, and appropriate imaging. Tools such as X-ray, ultrasound, and MRI are used to understand the joint; they are diagnostic instruments, not treatments. Ultrasound or fluoroscopy may also help guide an injection accurately to its target.

Conservative care usually comes first. Depending on the diagnosis, that can include activity modification, physical therapy, weight management where relevant, and appropriate use of established treatments. If a polynucleotide course such as Conjuran is considered reasonable, it may be planned as a short series rather than a single injection, and expectations should be set honestly: the aim is to support the joint environment, benefit is not guaranteed, and an injection does not replace surgery when surgery is genuinely indicated. Choosing a non-surgical path can be sensible for many people, but it does not guarantee that surgery will be avoided in the future. To discuss your specific circumstances, you can reach the clinic's English-speaking coordinator through the Nucellin contact page.

Who Might Be a Candidate

There is no universal formula for candidacy, and no article can determine whether Conjuran is right for you. In general terms, people sometimes considered for regenerative-oriented injections include those with mild-to-moderate joint symptoms who have not gained adequate relief from conservative care, who understand the emerging and limited nature of the evidence, and who hold realistic expectations. Candidacy also depends on excluding situations where an injection would be inappropriate, on the specific joint involved, and on overall health.

Only an in-person examination and diagnosis can establish whether a polynucleotide injection is a reasonable choice for a specific person. As Chief Director, Dr. Heejun Kim is a board-certified orthopedic surgeon (a Korean credential) whose background includes orthopedic surgery training at Severance Hospital, Yonsei University, along with a clinical teaching role there; he is also a regular member of numerous Korean and international orthopedic and regenerative-medicine societies, including the International Society for Medical Shockwave Treatment (ISMST). Nucellin Orthopedic Clinic is a Registered Medical Institution for Attracting Foreign Patients, certified by the Korean Ministry of Health and Welfare.

Risks and Limitations

As with any injection, a polynucleotide joint injection carries general risks, including temporary pain, swelling, or bruising at the site and a small risk of infection. Beyond these, the specific limitations of Conjuran deserve emphasis: the evidence base is limited, protocols are not standardized, long-term data are sparse, and the product is not FDA-approved in the United States. Product quality depends on the supply chain and the regulatory framework behind it.

The most important limitation is one of expectations. Conjuran is not a cure, does not guarantee relief, and should never be described as regrowing cartilage or reversing arthritis. It is one possible tool, with emerging and limited evidence, that a qualified physician may consider within an individualized, conservative-first plan. Being candid about that uncertainty is a sign of good care.

Frequently Asked Questions

Is Conjuran the same as hyaluronic acid?

No. Hyaluronic acid is framed primarily as a lubricating, cushioning viscosupplement and is an FDA-approved device for knee osteoarthritis in the U.S. Conjuran is a polynucleotide product marketed as regeneration-oriented rather than lubrication-only, and it is not FDA-approved. They are different materials with different intended roles.

Is Conjuran FDA-approved?

No. Conjuran, as a polynucleotide joint injection, is not FDA-approved in the United States. In contrast, hyaluronic acid viscosupplementation is FDA-approved, but only for knee osteoarthritis. At Nucellin Orthopedic Clinic, Conjuran is provided under Korean medical regulation.

Does Conjuran regenerate cartilage?

No. "Regeneration-oriented" describes the intended mechanism and marketing category, not a proven outcome. There is no credible basis for claiming that Conjuran regrows cartilage, reverses arthritis, or provides permanent, pain-free results. Early evidence is limited, and results vary.

How is a polynucleotide different from PDRN?

Both polynucleotides and polydeoxyribonucleotide (PDRN) are purified nucleotide-based materials studied in regenerative contexts, and they are related concepts. However, they are formulated and marketed differently and should not be assumed to be identical. A physician can explain the distinctions relevant to your situation.

How many Conjuran injections are needed?

There is no standardized answer. Conjuran is often given as a short series rather than a single injection, but the details depend on the joint, the diagnosis, and the treating physician's assessment. Any plan should be individualized after an examination.

Will U.S. insurance cover Conjuran?

Generally, no. Elective regenerative joint injections such as Conjuran are typically not covered by U.S. insurance, and because the care is provided in Korea under Korean regulation, U.S. coverage should not be assumed. Confirm financial details directly with the clinic.

Is Conjuran safe?

It carries the general risks of any injection, such as temporary soreness, swelling, bruising, or a small infection risk, and its safety also depends on product quality and proper technique. Because it is not FDA-approved in the U.S., the applicable framework is Korean regulation. A physician should review your health history before recommending it.

The Bottom Line

  • Conjuran is a polynucleotide (PN) joint injection marketed as regeneration-oriented rather than lubrication-only.
  • It is not FDA-approved in the United States; by contrast, hyaluronic acid viscosupplementation is FDA-approved but only for knee osteoarthritis.
  • At Nucellin Orthopedic Clinic, Conjuran is delivered under Korean medical regulation, not U.S. FDA oversight, and it is typically not covered by U.S. insurance.
  • Early evidence is limited and results vary; Conjuran is not a cure and does not regrow cartilage or guarantee relief.
  • Whether it is appropriate is decided by a physician after an in-person examination, with conservative measures generally considered first.

This article is for general educational purposes only and is not a self-diagnosis tool. It cannot replace an in-person evaluation, diagnosis, or personalized medical advice from a qualified clinician. Polynucleotide injections such as Conjuran are not FDA-approved in the United States, and any care described here is delivered at Nucellin Orthopedic Clinic under Korean medical regulation rather than U.S. FDA oversight. Outcomes vary from person to person, and no result is guaranteed. Whether any treatment is appropriate for you can only be determined through a professional examination.

More Articles

Continue reading our clinical guides.

View All

Learn More

Learn More

Medical Clinic

Dedicated to evidence-based medical care, personalized treatment planning, and comprehensive support for local and international patients.

Treatments

SpecialtiesServicesMedical TeamSpecial OffersMedical Articles

Patient Guide

About UsHow It WorksBefore & AfterPatient ReviewsPress & Media

Information & Legal

Contact & LocationSite SearchPrivacy PolicyRefund & Cancellation PolicyTerms of Use

© Medical Clinic. All rights reserved.

Individual clinical results may vary. Please consult a board-certified specialist.